PURPOSE OF REVIEW: Older obese persons with decreased muscle mass or strength are at special risk for adverse outcomes. We discuss potential pathways to muscle impairment in obese individuals and the consequences that joint obesity and muscle impairment may have on health and disability. Tantamount to this discussion is whether low muscle mass or, rather, muscle weakness should be used for the definition. RECENT FINDINGS: Excess energy intake, physical inactivity, low-grade inflammation, insulin resistance and changes in hormonal milieu may lead to the development of so-called 'sarcopenic obesity'. It was originally believed that the culprit of age-related muscle weakness was a reduction in muscle mass, but it is now clear that changes in muscle composition and quality are predominant. We propose that the risk of adverse outcomes, such as functional limitation and mortality, is better estimated by considering jointly obesity and muscle strength rather than obesity and muscle mass and the term 'sarcopenic obesity' should be revisited. SUMMARY: Recognition of obese patients who have associated muscle problems is an essential goal for clinicians. Further research is needed to identify new target for prevention and cure of this important geriatric syndrome.
PURPOSE OF REVIEW: Older obesepersons with decreased muscle mass or strength are at special risk for adverse outcomes. We discuss potential pathways to muscle impairment in obese individuals and the consequences that joint obesity and muscle impairment may have on health and disability. Tantamount to this discussion is whether low muscle mass or, rather, muscle weakness should be used for the definition. RECENT FINDINGS: Excess energy intake, physical inactivity, low-grade inflammation, insulin resistance and changes in hormonal milieu may lead to the development of so-called 'sarcopenic obesity'. It was originally believed that the culprit of age-related muscle weakness was a reduction in muscle mass, but it is now clear that changes in muscle composition and quality are predominant. We propose that the risk of adverse outcomes, such as functional limitation and mortality, is better estimated by considering jointly obesity and muscle strength rather than obesity and muscle mass and the term 'sarcopenic obesity' should be revisited. SUMMARY: Recognition of obesepatients who have associated muscle problems is an essential goal for clinicians. Further research is needed to identify new target for prevention and cure of this important geriatric syndrome.
Authors: P S Van Dam; H E Smid; W R de Vries; M Niesink; E Bolscher; E J Waasdorp; C Dieguez; F F Casanueva; H P Koppeschaar Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: L Ferrucci; S Bandinelli; E Benvenuti; A Di Iorio; C Macchi; T B Harris; J M Guralnik Journal: J Am Geriatr Soc Date: 2000-12 Impact factor: 5.562
Authors: M Visser; A B Newman; M C Nevitt; S B Kritchevsky; E B Stamm; B H Goodpaster; T B Harris Journal: Ann N Y Acad Sci Date: 2000-05 Impact factor: 5.691
Authors: Stephanie E Wohlgemuth; Hazel A Lees; Emanuele Marzetti; Todd M Manini; Juan M Aranda; Michael J Daniels; Marco Pahor; Michael G Perri; Christian Leeuwenburgh; Stephen D Anton Journal: Rejuvenation Res Date: 2011-06-01 Impact factor: 4.663
Authors: M Inzitari; E Doets; B Bartali; V Benetou; M Di Bari; M Visser; S Volpato; G Gambassi; E Topinkova; L De Groot; A Salva Journal: J Nutr Health Aging Date: 2011-08 Impact factor: 4.075
Authors: Nicolaas E P Deutz; Jürgen M Bauer; Rocco Barazzoni; Gianni Biolo; Yves Boirie; Anja Bosy-Westphal; Tommy Cederholm; Alfonso Cruz-Jentoft; Zeljko Krznariç; K Sreekumaran Nair; Pierre Singer; Daniel Teta; Kevin Tipton; Philip C Calder Journal: Clin Nutr Date: 2014-04-24 Impact factor: 7.324